Risk of recalls and shipment suspensions due to product quality issues
First written in FY2025. 1 of 2 entries say "Mitigated", first in FY2026. Latest entry: FY2026.
0 other companies' latest entry also says "Mitigated".
- FY2026MitigatedAnnual report
「In line with its management policy of providing high-quality, distinctive products and services, the group manufactures pharmaceuticals under a management system and standards compliant with GMP (Good Manufacturing Practice for Pharmaceuticals), under the supervision of GQP (Good Quality Practice for Pharmaceuticals, quasi-drugs, cosmetics and medical devices). The group pursues consistent quality assurance from the procurement and storage of raw materials through pharmaceutical manufacturing and distribution, and complies with stringent inspections by regulatory authorities in Japan and overseas.」
The response to product quality risks is described in concrete terms, including management based on GQP and GMP, consistent quality assurance from raw materials through distribution, and compliance with regulatory inspections. - FY2025First statedAnnual report
「However, if a product quality issue arises and causes harm to health, the group's business performance and financial condition could be affected by costs associated with product recalls and liability for damages, product shortages caused by shipment suspensions, and damage to its social credibility.」
The document separately identified health damage, recalls, compensation, shipment suspensions, product shortages and reputational damage resulting from product quality issues as major risks. It also outlined responses involving GMP and supplier audits.